Skip to content
value.today

Transcode Therapeutics, Inc.

Transcode Therapeutics, Inc. is listed today as TransCode Therapeutics, Inc.: market value, financials and filings are on its company page.

Funding rounds

0 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Transcode Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2024$8 MPrivate placement after listing$2 to $10 million

Transcode Therapeutics, Inc.: Private sale, Dec 2024

Investors in this round

6 investors had bought by the notice of Dec 12, 2024: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 2 investors are named for Transcode Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$8 M of $8 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
$320,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Thomas A. Fitzgerald · Executive Officer, Director
  • Erik A. Manting · Director
  • Magda A. Marquet · Director
  • Philippe A. Calais · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • The Benchmark Company LLC (CRD 000022982) · New York, New YorkSold in all US states
  • A.G.P./Alliance Global Partners (CRD 000008361) · Westport, ConnecticutSold in all US states

Remarks in the notice

  • On fees: “The Benchmark Company LLC acted as the exclusive placement agent for the Private Placement and the Company paid them a cash fee. Also, the Company engaged A.G.P./Alliance Global Partners as financial advisor and paid them an expense fee and a cash fee.”

Signed by Thomas A. Fitzgerald, Interim Chief Executive Officer; Chief Financial Officer. Source: SEC Form D, newest notice filed Dec 12, 2024. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Transcode Therapeutics, Inc. had no revenue when it filed its newest notice of a funding round (Dec 2024).

    SEC Form D (revenue range) · Dec 2024

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Dec 2024

Products and services#

No products or services of Transcode Therapeutics, Inc. are on record.

Investors#

2 named in official filings. Open an investor to see everything it has backed.

Investors in Transcode Therapeutics, Inc.
InvestorKindAmountRoundRoleSource
CK Life Sciences Intl (Holdings) IncCompanynot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2026)SEC Form 3
Defj, LLCOthernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2026)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete.

Largest shareholders today

Institutions holding TransCode Therapeutics, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Transcode Therapeutics, Inc.
NameRoleNamed in
Thomas A. FitzgeraldExecutive officerDec 2024
Erik A. MantingDirectorDec 2024
Magda A. MarquetDirectorDec 2024
Philippe A. CalaisDirectorDec 2024
Thomas A. FitzgeraldDirectorDec 2024

Went public since 2021. Its SEC number is that of a company listed on a stock exchange.